❇️ **Evidence status:** No human or dedicated animal studies. All claims extrapolated from its parent compound, Semax. ❇️ What it is Adamax is a synthetic modification of Semax, the Russian-developed nootropic peptide. Chemically it's written as Ac-MEHFPGP-adamantyl, sometimes described as N-Acetyl Semax Adamantane. It's occasionally called "Super Semax" in research circles. ❇️ How it works The starting point is Semax, a fragment of the ACTH hormone (specifically the ACTH 4-7 region, sequence Met-Glu-His-Phe-Pro-Gly-Pro). Semax has decades of Russian clinical use and research behind it, mostly in stroke rehabilitation and cognitive function, and it's thought to work partly by raising BDNF. Adamax adds two changes to that backbone. An acetyl group at one end slows enzymatic breakdown. An adamantane group, which is a rigid cage-shaped carbon structure, is attached at the other end. Adamantane is very fat-soluble, and the theory is that it helps the molecule cross cell membranes and the blood-brain barrier more readily, while also resisting degradation. The result should, in theory, be a longer-lasting and more brain-penetrant version of Semax. ❇️ What the research shows This is where honesty matters. There are no published human trials on Adamax specifically. There is no dedicated clinical dataset. Essentially every claim made about Adamax is extrapolated from Semax research or from general work on adamantane-modified neurotrophic peptides. Those adamantane-peptide designs do have preclinical support for improving learning, neurogenesis, and synaptogenesis in animal models. But that's the compound class, not this compound. The Semax foundation is more solid. The long-running Russian work, including Ashmarin's review of fifteen years of Semax design and study, reported that intranasal Semax affected working memory and attention, with effects described as lasting on the order of a day. So: a well-studied parent compound, a chemically sensible modification, and no direct evidence.